

Please try another search
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. The company has a license agreement with Yale University. NextCure, Inc. was incorporated in 2015 and is headquartered in Beltsville, Maryland.
Name | Age | Since | Title |
---|---|---|---|
David S. Kabakoff | 74 | 2015 | Independent Chairman of the Board |
Elaine V. Jones | 67 | 2015 | Independent Director |
Garry A. Nicholson | 67 | 2020 | Independent Director |
John G. Houston | 62 | 2020 | Independent Director |
Weiping Zou | - | 2021 | Member of Scientific Advisory Board |
Ursula A. Matulonis | - | 2021 | Member of Scientific Advisory Board |
Chau Quang Khuong | 46 | 2015 | Independent Director |
Stephen D. Miller | - | - | Member of Scientific Advisory Board |
Michael S. Richman | 61 | 2015 | Co-Founder, CEO, President & Director |
Stephen W. Webster | 61 | 2019 | Independent Director |
Mario Sznol | 64 | - | Member of Scientific Advisory Board |
Elizabeth M. Jaffee | - | 2021 | Member of Scientific Advisory Board |
Anne Elizabeth Borgman-Hagey | 54 | 2021 | Independent Director |
Ellen G. Feigal | 68 | 2021 | Independent Director |
Lieping Chen | 64 | 2015 | Co-Founder & Chairman of Scientific Advisory Board |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review